Page 7 - Robert Barrow News Today

Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) have received an average recommendation of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on […]

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on […]

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) CEO Robert Barrow sold 13,499 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $3.58, for a total transaction of $48,326.42. Following the sale, the chief executive officer now directly owns 611,729 shares in […]

– 198 participants dosed across 20 clinical sites – – On track for topline results in Q4 2023 – ...

Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) have received a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock […]

– Enhances financial flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates – - The Company’s ending 2Q2023 cash and cash equivalents of $116.9 million and... -Today at 07:31 am- MarketScreener

Company Logo MindMed Investor Presentation August 2023 Disclaimer This presentation has been prepared by Mind Medicine Inc. solely for informational purposes. None of... -Today at 05:35 pm- MarketScreener

AdvisorShares Investments LLC reduced its position in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 17.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 93,310 shares of the company’s stock after selling 20,127 shares during the […]

Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this:

A strong commandant system works, but only if the person selected is wise, not delusional.